223 related articles for article (PubMed ID: 31511184)
21. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.
Zafari Z; Lynd LD; FitzGerald JM; Sadatsafavi M
J Allergy Clin Immunol; 2014 Oct; 134(4):908-915.e3. PubMed ID: 24875619
[TBL] [Abstract][Full Text] [Related]
22. Economic Evaluations of Multicomponent Disease Management Programs with Markov Models: A Systematic Review.
Kirsch F
Value Health; 2016 Dec; 19(8):1039-1054. PubMed ID: 27987631
[TBL] [Abstract][Full Text] [Related]
23. Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations.
Elliott J; van Katwyk S; McCoy B; Clifford T; Potter BK; Skidmore B; Wells GA; Coyle D
Pharmacoeconomics; 2019 Oct; 37(10):1261-1276. PubMed ID: 31201643
[TBL] [Abstract][Full Text] [Related]
24. The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal.
McManus E; Sach T; Levell N
Pharmacoeconomics; 2018 Jan; 36(1):51-66. PubMed ID: 28864846
[TBL] [Abstract][Full Text] [Related]
25. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?
Dilokthornsakul P; Chaiyakunapruk N; Campbell JD
J Asthma; 2017 Jan; 54(1):17-23. PubMed ID: 27284904
[TBL] [Abstract][Full Text] [Related]
26. The Cost-Effectiveness of Digital Health Interventions on the Management of Cardiovascular Diseases: Systematic Review.
Jiang X; Ming WK; You JH
J Med Internet Res; 2019 Jun; 21(6):e13166. PubMed ID: 31210136
[TBL] [Abstract][Full Text] [Related]
27. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
[TBL] [Abstract][Full Text] [Related]
28. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath.
Harnan SE; Tappenden P; Essat M; Gomersall T; Minton J; Wong R; Pavord I; Everard M; Lawson R
Health Technol Assess; 2015 Oct; 19(82):1-330. PubMed ID: 26484874
[TBL] [Abstract][Full Text] [Related]
29. Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial.
De Vera MA; Sadatsafavi M; Tsao NW; Lynd LD; Lester R; Gastonguay L; Galo J; FitzGerald JM; Brasher P; Marra CA
Trials; 2014 Dec; 15():488. PubMed ID: 25494702
[TBL] [Abstract][Full Text] [Related]
30. Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations.
Gavan S; Bruce I; Payne K
Lupus Sci Med; 2020 Jul; 7(1):. PubMed ID: 32723809
[TBL] [Abstract][Full Text] [Related]
31. Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD.
Einarson TR; Bereza BG; Nielsen TA; Van Laer J; Hemels ME
J Med Econ; 2016; 19(4):319-55. PubMed ID: 26535917
[TBL] [Abstract][Full Text] [Related]
32. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: A systematic review and critical appraisal of decision-analytic models.
Usman M; Khunti K; Davies MJ; Gillies CL
Diabetes Res Clin Pract; 2020 Mar; 161():108073. PubMed ID: 32061637
[TBL] [Abstract][Full Text] [Related]
34. Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review.
Di Tanna GL; Bychenkova A; O'Neill F; Wirtz HS; Miller P; Ó Hartaigh B; Globe G
Pharmacoeconomics; 2019 Mar; 37(3):359-389. PubMed ID: 30596210
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
Wong CKH; Liao Q; Guo VYW; Xin Y; Lam CLK
Vaccine; 2017 May; 35(24):3153-3161. PubMed ID: 28476628
[TBL] [Abstract][Full Text] [Related]
36. Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease.
Hernandez L; Ozen A; DosSantos R; Getsios D
Pharmacoeconomics; 2016 Jul; 34(7):681-707. PubMed ID: 26899832
[TBL] [Abstract][Full Text] [Related]
37. Measuring costs and consequences in economic evaluation in asthma.
Sculpher MJ; Price M
Respir Med; 2003 May; 97(5):508-20. PubMed ID: 12735668
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients.
Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
J Asthma; 2016 Jun; 53(5):538-45. PubMed ID: 26786524
[TBL] [Abstract][Full Text] [Related]
39. Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment.
Darab MG; Engel L; Henzler D; Lauerer M; Nagel E; Brown V; Mihalopoulos C
Appl Health Econ Health Policy; 2024 Jul; 22(4):503-525. PubMed ID: 38554246
[TBL] [Abstract][Full Text] [Related]
40. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
